-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pfizer has received EU approval for the biosimilar Ruxience (rituximab) biosimilar to CD20 monomera (rituxira, mabThera, rituximab)approved for the use of Ruxience for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granuloma with polyvascularitis (GPA) and micropolyvasitis (MPA) and common herpes (PV)the decision was based on a series of data on the biological similarity of Ruxience and MabThera, including results from a clinical comparative study of REFLECTIONS B3281006, which evaluated Ruxience's efficacy, safety, immunoogenics, pharmacokinetics, and pharmacodynamic parametersThe data showed that Ruxience "had no clinically significant difference sable in CD20-positive, low tumor-loaded follicles patients with the safety or efficacy of MabThera." Masum Hossain, regional president ofPfizer Oncology International Development Market, added: "Biosimilars like Ruxience have similar safety and efficacy to the original product and can significantly reduce healthcare costs"